3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Sarcoma
1
Conditions
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Hemangiosarcoma
1
Interventions
Fulvestrant
83
Letrozole
77
Paclitaxel
76
pembrolizumab
72
Specimen Handling
66
Trastuzumab
62
Carboplatin
57
Magnetic Resonance Spectroscopy
51
ribociclib
49
Capecitabine
48
Anastrozole
47
pertuzumab
46
palbociclib
43
exemestane
40
abemaciclib
40
Cyclophosphamide
40
Tamoxifen
39
Biopsy
38
Docetaxel
30
trastuzumab deruxtecan
29
Taxes
28
Radiotherapy
28
Gemcitabine
25
Blood Specimen Collection
25
130-nm albumin-bound paclitaxel
25
olaparib
22
Surveys and Questionnaires
22
Standard of Care
22
sacituzumab govitecan
20
eribulin
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
SGN-LIV1A
×
Breast
×
90 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled
NCT03424005
2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2
Recruiting
792 enrolled